We are executive search and leadership development specialists working to build a better future. As advisors and consultants to companies at the cutting edge of Health, Science, and Technology, we are united by our mission to build teams that change the world. Operating uniquely as one global team, we have honed our expertise, platform, and data for over two decades, working across three continents, and in 40 countries. Applying what we learn through our work with boards, leadership teams, and investors in the world’s most innovative companies, we bring together and develop the right people at the right time to propel them to achieve their worthwhile goals.
The Coulter Partners team is made up of 110 experts, working in 40 countries, holding 250,000 conversations with industry leaders each year. Together we channel data and learning to the benefit of our clients. We are a diverse group of experts with backgrounds ranging from science and technology, to the arts, finance, and more. Our reward system is designed to drive one-team behaviors and we work together seamlessly to combine industry experience and global insight with our passion for progress. Our team understands and is up to date with the challenges you face and the opportunities your business can maximize. This means we can find and develop exceptional individuals to drive you forward.
Our network is carefully curated and gives us access to leaders who can guide science, technology and innovation-driven companies through all stages of growth and evolution. Our executive search is an end-to-end process, underpinned by rigorous data and analytics from our dedicated Business Intelligence function and CP:Net™, our proprietary AI-driven candidate and company database. Our Board Advisory brings over two decades’ experience in building, advising and evolving boards for private and public companies. We understand what value a board can bring and how to evaluate its suitability for the stage of the business and the 3–5-year plan. We also provide leadership advisory at every step of the way. We have a network of mentors and advisors that bring the next level of insight to your organization, to build teams that change the world.
LONDON, U.K., January 23, 2017 — Coulter Partners was delighted to partner with BONESUPPORT AB to secure the appointment of Björn Westberg as Chief Financial Officer and Director. A Scandinavian medical technology company, BONESUPPORT AB is an emerging leader in innovative injectable bioceramic bone scaffolds to treat bone voids caused by trauma, infection, disease or related surgery. Mr
LONDON, UK, January 8, 2017 – Coulter Partners was delighted to partner with global biotechnology company, Therachon to secure the appointment of Hans Schikan, Pharm.D., as a non- executive director to the Board of Directors. Therachon focuses on developing treatments for rare, genetic diseases that currently have no available treatments. Their lead pipeline candidate, TA-46, is
LONDON, U.K., January 4, 2017 — Coulter Partners was delighted to partner with Albumedix to secure the appointment of Dr. Giles Campion as Chief Medical Officer. Albumedix develops albumin-enabled therapeutics using its albumin-based products and technologies for advanced drug and vaccine formulation, extended drug half-life and improved drug delivery. Using its products and technologies, Albumedix is advancing
LONDON, U.K., December 1, 2016 — Coulter Partners was delighted to partner once again with Medigene AG to secure the appointment of Dr. Thomas Taapken as Chief Financial Officer. Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. The Company develops highly innovative, complementary treatment platforms to target various
LONDON, U.K., November 8, 2016 — Coulter Partners was delighted to partner once more with Erytech Pharma to secure the appointment of Dr. Alexander Scheer as Chief Scientific Officer. ERYTECH Pharma (Euronext Paris:ERYP) (Paris:ERYP) (ADR:EYRYY) is a French biopharmaceutical company developing ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs. “Alexander brings a
News
Top hires for Q3-2025
Top hires for Q2-2025
Coulter Partners: Fostering Digital Health connections on the Seine
Coulter Partners at BIA Women in Biotech: Driving diversity in Life Sciences leadership
Coulter Partners joins key discussion on HealthTech Boards at NHS Innovation Accelerator day
Coulter Partners at the BIA Life Science Leadership Summit: Fostering Board Excellence and UK Biotech Growth!
Coulter Partners attends LabCentral’s Luminescence: Rise & Fund event in Boston, MA
Leadership in MedTech: Key insights from our Paris roundtable
Coulter Partners co-hosts premier UK HealthTech Super Connector event
Coulter Partners attends Bio€quity Europe in Bruges, Belgium
Coulter Partners attends Danish Biotech Spring Gala
Top hires for VC & PE portfolio companies Q1-2025
Evolution Italy: Life Science leaders gather for insightful discussions
Coulter Partners at BioCapital Europe 2025: Innovation and optimism reign
BioInnovation Institute Breakfast Seminar Health Tech Ecosystem – Copenhagen
BIA Gala Dinner 2025
Top hires for VC & PE portfolio companies Q4-2024
Top global hires for large-cap, mid-cap and public companies H2-2024